Bohemine


Catalog No. size PriceQuantity
M6686-2 2mg solid $116
M6686-10 10mg solid $476

Description

Cas:189232-42-6

Product Information

Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine..

 

Chemical Formula: C18H24N6O

 

Exact Mass: 340.20116

 

Molecular Weight: 340.43 

 

Elemental Analysis: C, 63.51; H, 7.11; N, 24.69; O, 4.70

 

Synonym: 

 

bohemine

189232-42-6

3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol

3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol

CHEMBL83980

CHEBI:86007

2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine

3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol

1-Propanol, 3-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-

purine deriv. 1

GTPL5938

SCHEMBL1443403

BDBM10633

CTK8A4395

[6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine

2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine

AOB6160

DTXSID00274365

EX-A931

HMS3229C10

HMS3674K11

3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]propan-1-ol

BCP15150

ZINC2002752

HSCI1_000064

s6531

Bohemine, >=95% (HPLC), powder

AKOS026750317

CCG-206821

NCGC00165739-01

NCGC00165739-02

HY-12843

CS-0012711

FT-0700250

J-012209

BRD-K38622899-001-01-4

Q27075423

3-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]propan-1-ol

6-(benzylamino)-2-[(3-hydroxypropyl)amino]-9-isopropylpurine

3-{[6-(Benzylamino)-9-Isopropyl-9H-Purin-2-Yl]Amino}-1-Propanol

 

Chemical Name:

3-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol

 

InChi Key:

OPQGFIAVPSXOBO-UHFFFAOYSA-N

 

InChi Code:    InChI=1S/C18H24N6O/c1-13(2)24-12-21-15-16(20-11-14-7-4-3-5-8-14)22-18(23-17(15)24)19-9-6-10-25/h3-5,7-8,12-13,25H,6,9-11H2,1-2H3,(H2,19,20,22,23)

 

Smiles Code:

CC(N1C=NC2=C1N=C(NCCCO)N=C2NCC3=CC=CC=C3)C

 

 

Technical Data:

 

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

 

In Vitro

Bohemine (0-30 µM; 72 hours; ME-750 cells) treatment inhibits cell growth. Addition of Bohemine at concentrations in the range of 1-10 µM results in a short-term arrest of growth and of monoclonal antibody production. The short-term suppression of cell functions is followed by a significant temporary increase of specific growth rate and of specific production rate.

Hybridoma cells are retarded both at the G1/S boundary and at the G2/M boundary, depending on Bohemine (0-30 µM) concentration.

T-lymphoblastic cell line CEM is treated by Bohemine, five proteins are found to be downregulated, namely α-enolase, triosephosphate isomerase, initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins play significant roles in glycolysis, proteosynthesis, and in cytoskeleton rearrangement.

Bohemine inhibits growth of human tumor cell lines with an IC50 of 27 µM.

 

In Vivo

Bohemine (50 mg/kg; intravenous injection; BALB/c mice) treatment shows Cmax is 72,308 nM, observed clearance is 0.23 L/h and T1/2 is 1.39 h.

 

 

References

 

  1. Novakova O, Liskova B, Vystrcilova J, Suchankova T, Vrana O, Starha P, Travnicek Z, Brabec V. Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine. Eur J Med Chem. 2014 May 6;78:54-64. doi: 10.1016/j.ejmech.2014.03.041. Epub 2014 Mar 15. PubMed PMID: 24675180.

 

  1. Liskova B, Zerzankova L, Novakova O, Kostrhunova H, Travnicek Z, Brabec V. Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues. Chem Res Toxicol. 2012 Feb 20;25(2):500-9. doi: 10.1021/tx200525n. Epub 2012 Feb 1. PubMed PMID: 22250642.

 

  1. Kovarova H, Halada P, Man P, Dzubak P, Hajduch M. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol Cancer Res Treat. 2002 Aug;1(4):247-56. PubMed PMID: 12625783.

 

  1. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res. 2005 Jul 1;11(13):4875-87. PubMed PMID: 16000586.

 

Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed